Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 15/20 | 0.46 |
| ▸ | PPARD | Q03181 | 4/20 | 0.44 |
| ▸ | PPARG | P37231 | 10/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19469595 | 1.00 | PPARA (0.46) | PPARAPPARDPPARGSRD5A1SRD5A2 | |
| SCHEMBL19469681 | 1.00 | PPARA (0.46) | PPARAPPARDPPARGSRD5A1SRD5A2 | |
| SCHEMBL8653315 | 0.87 | AKT1 (0.50) | PPARAPPARDPPARGRXRA | |
| SCHEMBL19469478 | 0.85 | PPARA (0.48) | PPARASRD5A1SRD5A2CYP2D6CYP2C9 | |
| SCHEMBL29495290 | 0.85 | PPARA (0.48) | PPARASRD5A1SRD5A2CYP2D6CYP2C9 | |
| SCHEMBL29495503 | 0.85 | PPARA (0.48) | PPARASRD5A1SRD5A2CYP2D6CYP2C9 | |
| SCHEMBL19469461 | 0.85 | PPARA (0.48) | PPARASRD5A1SRD5A2CYP2D6CYP2C9 | |
| SCHEMBL19469463 | 0.85 | PPARA (0.48) | PPARASRD5A1SRD5A2CYP2D6CYP2C9 | |
| SCHEMBL19469539 | 0.85 | GAA (0.39) | PPARAPPARDPPARGSRD5A1SRD5A2 | |
| SCHEMBL22798929 | 0.82 | PPARA (0.44) | PPARAPPARDPPARGSRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109219602-A | Modulators of cystic fibrosis transmembrane conductance regulator proteins | 艾伯维公司 | 2019-01-15 | — | — | CN | disclosed |
| US-10118916-B2 | Modulators of cystic fibrosis transmembrane conductance regulator protein | ABBVIE S.Á.R.L. (LU) | 2018-11-06 | — | — | US | disclosed |
| WO-2017187321-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | AbbVie S.à.r.l. (LU) | 2017-11-02 | — | — | WO | disclosed |
| US-20170305891-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | ABBVIE S.Á.R.L. (LU) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305891-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | CFTR, CHRM2, CHRM1 | PPARA 2278/4885PPARD 1813/4885PPARG 1217/4885 |
| US-10118916-B2 | Modulators of cystic fibrosis transmembrane conductance regulator protein | CFTR, CHRM2, CHRM1 | PPARA 2278/4885PPARD 1813/4885PPARG 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.